Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
30 Maio 2023 - 9:03AM
Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”)
(Nasdaq: CPRX), a commercial-stage biopharmaceutical company
focused on in-licensing, developing, and commercializing novel
medicines for patients living with rare diseases, today
announced the appointment of Ms. Tamar Thompson to the
Company's Board of Directors ("Board"), effective on May 25, 2023.
"We are extremely pleased to welcome Tamar
to our Board as she brings a wealth of experience to our team
across several therapeutic categories, including rare diseases,
coupled with extensive health policy and government affairs
acumen," said Patrick J. McEnany, Chairman and CEO of
Catalyst. "Ms. Thompson's distinguished industry expertise and
leadership ideally align with Catalyst’s long-term growth strategy.
We look forward to her valuable contributions as we continue
executing our expansion initiatives to provide innovative rare
neuroscience disease medicines to more patients seeking novel
treatment options."
"I am honored to join the Catalyst Board at
such a pivotal time in the Company’s history," said Ms. Thompson.
"Catalyst has experienced a very successful evolution over the last
few years and is well positioned to further capitalize on its
established capabilities with additional novel assets that
complement its growing product portfolio. I look forward to
collaborating with the Board and the Catalyst’s leadership team as
the Company advances its strategic growth plans."
Ms. Thompson has more than twenty years of
leadership experience in health care, health policy strategy,
government affairs, and market access, with a diverse background
across multiple healthcare sectors and therapeutic categories,
including rare diseases, with a focus on developing strategic and
tactical recommendations to ensure optimal reimbursement and market
access for rare disease products. Ms. Thompson currently serves as
Vice President, Head of Global Corporate Affairs for Alexion
Pharmaceutical, AstraZeneca Rare Diseases. Prior to joining
Alexion, Ms. Thompson served as Executive Director, State
Government Affairs and Federal Policy for Bristol-Myers Squibb
Company. Prior to joining Bristol Myers Squibb, she served as a
strategic policy advisor and consultant for various governmental
affairs firms based in Washington, D.C.
Ms. Thompson received a Master of Science in
Health Sciences with a concentration in Public Health from Trident
University in Cypress, California, and currently serves on the
Board of Directors of Avidity Biosciences.
About Catalyst
PharmaceuticalsWith exceptional patient focus, Catalyst is
committed to developing and commercializing innovative
first-in-class medicines that address rare neurological and
epileptic diseases. Catalyst's flagship U.S. commercial product is
FIRDAPSE® (amifampridine) Tablets 10 mg, approved for the treatment
of Lambert-Eaton myasthenic syndrome ("LEMS") for adults and for
children ages six to seventeen. In January 2023, Catalyst acquired
the U.S. commercial rights to FYCOMPA® (perampanel) CIII, a
prescription medicine approved in people with epilepsy aged four
and older alone or with other medicines to treat partial-onset
seizures with or without secondarily generalized seizures and with
other medicines to treat primary generalized tonic-clonic seizures
for people with epilepsy aged 12 and older. Further, Canada's
national healthcare regulatory agency, Health Canada, has approved
the use of FIRDAPSE for the treatment of adult patients
in Canada with LEMS.
For Full Prescribing and Safety Information for
FIRDAPSE®, please visit www.firdapse.com. For Full Prescribing
Information, including Boxed WARNING for FYCOMPA®, please
visit www.fycompa.com. For more information about Catalyst
Pharmaceuticals, Inc., visit the Company's website
at www.catalystpharma.com.
Forward-Looking StatementsThis
press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which
may cause Catalyst's actual results in future periods to differ
materially from forecasted results. A number of factors, including
those factors described in Catalyst's Annual Report on Form 10-K
for the fiscal year 2022 and its other filings with the U.S.
Securities and Exchange Commission ("SEC"), could adversely affect
Catalyst. Copies of Catalyst's filings with the SEC are available
from the SEC, may be found on Catalyst's website, or may be
obtained upon request from Catalyst. Catalyst does not undertake
any obligation to update the information contained herein, which
speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Relations Contact:
Mary Coleman
Catalyst Pharmaceuticals
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact:
David Schull
Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024